Literature DB >> 19732604

Antiphospholipid syndrome.

Diane George1, Doruk Erkan.   

Abstract

The antiphospholipid syndrome (APS) is an autoimmune systemic disease that is diagnosed when there is vascular thrombosis and/or pregnancy morbidity occurring with persistently positive antiphospholipid antibodies (aPL) (lupus anticoagulant test, anticardiolipin antibodies, and/or anti-beta(2)-glycoprotein I antibodies). Although International APS Classification Criteria have been formulated to provide a uniform approach to APS research, aPL may cause a spectrum of clinical manifestations, some of which are not included in these criteria. The main aPL-related cardiac manifestations include valve abnormalities (vegetations and/or thickening), myocardial infarction (MI), intracardiac thrombi, and myocardial microthrombosis. In this article, we will review the definition, etiopathogenesis, clinical manifestations, diagnosis, and treatment of aPL-related clinical events with emphasis on cardiac manifestations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732604     DOI: 10.1016/j.pcad.2009.06.005

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  20 in total

Review 1.  [Cardiopulmonary emergencies during pregnancy and the postpartum period].

Authors:  M Rosenberg; N Frey
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-10       Impact factor: 0.840

2.  Neonatal septic arthritis: Indian perspective.

Authors:  Akash Rai; Debrup Chakladar; Souravi Bhowmik; Tanushree Mondal; Arnab Nandy; Biplab Maji; Avijit Hazra; Rakesh Mondal
Journal:  Eur J Rheumatol       Date:  2019-09-05

3.  IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE.

Authors:  Caroline Grönwall; Ehtisham Akhter; Cheongeun Oh; Rufus W Burlingame; Michelle Petri; Gregg J Silverman
Journal:  Clin Immunol       Date:  2012-01-14       Impact factor: 3.969

4.  Recurrent acute coronary events in a young adult.

Authors:  Suman B Thapamagar; Thein T Aung; Daniel Mascarenhas
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

5.  Paradoxical embolism causing acute embolic events in a patient with hereditary thrombophilia.

Authors:  L Tang; Z F Fang; S H Zhou
Journal:  Herz       Date:  2013-10-25       Impact factor: 1.443

6.  Chronic total occlusions of the right coronary and left anterior descending coronary arteries in a young adult patient with antiphospholipid syndrome.

Authors:  Yasuyuki Kawai; Michihiko Kitayama; Atsushi Motoyama; Minoru Wakasa; Ryuhei Saito; Hirofumi Aoki; Kousuke Fujibayashi; Makoto Watanabe; Takaaki Takamura; Hironobu Akao; Taketsugu Tsuchiya; Kouji Kajinami
Journal:  J Cardiol Cases       Date:  2016-04-11

7.  Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction.

Authors:  Loukianos S Rallidis; Argyri Gialeraki; Georgios Tsirebolos; Stylianos Tsalavoutas; Maria Rallidi; Efstathios Iliodromitis
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

8.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

9.  Impact of antiphospholipid syndrome iBook on medical students' improvement of knowledge: An international randomized controlled study.

Authors:  Stephane Zuily; Laurent Phialy; Ecem Sevim; Eloïse Germain; Ozan Unlu; Virginie Dufrost; Jessie Risse; Isabelle Clerc-Urmès; Cédric Baumann; Jessica R Berman; Michael D Lockshin; Denis Wahl; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2019-09-05

Review 10.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.